Oncology Hematology Care U.S. Oncology

Cincinnati, Ohio, United States

Oncology Hematology Care U.S. Oncology

Cincinnati, Ohio, United States
SEARCH FILTERS
Time filter
Source Type

Spigel D.R.,Sarah Cannon Research Institute Tennessee Oncology PLLC | Mekhail T.M.,Florida Hospital Cancer Institute | Waterhouse D.,Oncology Hematology Care U.S. Oncology | Hadley T.,Norton Cancer Institute | And 4 more authors.
Cancer Investigation | Year: 2017

Background: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC. Methods: Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m2 IV, and carboplatin AUC = 6 IV every 21 days. After 6 cycles, maintenance therapy with panitumumab and pemetrexed was administered every 21 days until progressive disease or unacceptable toxicity. Results: 29 of 66 patients (44%) had objective responses. The median TTP was 6 months; median overall survival (OS) was 17 months. Panitumumab increased treatment-related toxicity, notably skin rash. Conclusions: The addition of panitumumab increased toxicity, and had no discernible impact on efficacy. © 2017 Taylor & Francis Group, LLC

Loading Oncology Hematology Care U.S. Oncology collaborators
Loading Oncology Hematology Care U.S. Oncology collaborators